文献速递淋巴瘤

复发或难治性弥漫性大B细胞淋巴瘤早期临床试验的风险获益:系统综述与Meta分析

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.
PubMed 文献 · Lancet Haematol · 2026-01-01

该系统综述与Meta分析纳入2000年至2025年间132项1-2期试验、共7786例复发或难治性弥漫性大B细胞淋巴瘤患者,评估不同药物类别的抗肿瘤活性与安全性。

核心结论

  • 自2000年以来复发或难治性弥漫性大B细胞淋巴瘤早期试验缓解率翻倍以上,主要由细胞治疗和双特异性抗体驱动,治疗相关死亡率保持低位。
  • 结果为临床医生、研究者和监管机构提供了早期试验的风险获益趋势与当代基准。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase.com、Web of Science和Wiley/Cochrane Library自建库至2025年5月9日。
  • 纳入2000年1月1日至2025年5月9日发表的英文1-2期试验,对象为18岁及以上复发或难治性弥漫性大B细胞淋巴瘤成人患者。
  • 共纳入132项试验、7786例患者,女性3375例(43%),男性4411例(57%)。
  • 主要结局为客观缓解率和完全缓解率,采用随机效应广义线性混合模型合并;不良事件为次要结局。
  • 研究注册于PROSPERO,CRD42023394451。

临床怎么用

  • 临床医生可参考不同药物类别的缓解率基准,尤其是细胞治疗和双特异性抗体的较高缓解率。
  • 早期试验中治疗相关死亡率低于1%,支持在复发或难治性弥漫性大B细胞淋巴瘤中开展早期临床试验的风险获益评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The treatment landscape for relapsed or refractory diffuse large B-cell lymphoma has changed profoundly with the introduction of novel drug classes, some approved solely on the basis of single-arm early-phase trials. We aimed to evaluate antitumour activity and safety outcomes across drug classes in early-phase trials in relapsed or refractory diffuse large B-cell lymphoma since 2000. METHODS: We did a systematic review and meta-analysis of phase 1-2 trials. We searched PubMed, Embase.com, Web of Science and Wiley/Cochrane Library from database inception to May 9, 2025. We included English-language studies published between Jan 1, 2000, and May 9, 2025, enrolling adults aged 18 years or older with relapsed or refractory diffuse large B-cell lymphoma treated with experimental agents alone or combined with CD20-antibodies; trials including other B-cell malignancies were eligible if diffuse large B-cell lymphoma-specific responses could be extracted. Trials restricted to highly-selected subgroups, supportive-care, administration-routes, country-specific approvals, and conference abstracts were excluded. Two investigators independently extracted summary data. The primary outcomes were objective response rate and complete response rate, and were pooled using random-effects generalised linear mixed models. Adverse events were secondary outcomes. Prespecified subgroup analyses evaluated drug class and publication period. The study was registered with PROSPERO, CRD42023394451. FINDINGS: We identified 2797 citations, of which 1824 unique records remained after removal of duplicates. 132 trials including 7786 patients were eligible for analysis. 3375 (43%) of 7786 patients were female and 4411 (57%) were male. Objective response rate was 30·5% (95% CI 26·0-35·5, I2=84·7%) and complete response rate 14·3% (11·5-17·7, I2=82·2%). Response rates varied across drug classes, with the highest objective response rate or complete response rate for cellular therapies (70·0%, 95% CI 61·0-77·0 and 51·0%, 95% CI 43·0-59·0), followed by bispecific antibodies (46·0%, 38·0-53·0 and 30·0%, 24·0-36·0) and antibody-drug conjugates (40·0%, 32·0-47·0 and 18·0%, 13·0-24·0). Objective response rate increased over time, from 16·6% (95% CI 9·0-29·0) in 2000-08 to 36·8% (30·0-45·0) in 2018-25. The overall rate of dose-limiting-toxicities or discontinuations was 6·0% (95% CI 4·7-7·6). The rate of grade 3-4 adverse events was 61·5% (95% CI 54·2-68·3), treatment-related-mortality was 0·6% (0·4-1·0), and non-relapse-mortality was 3·6% (2·9-4·5). Treatment-related mortality remained below 1% over time. INTERPRETATION: Since the year 2000, early-phase trials in relapsed or refractory diffuse large B-cell lymphoma have shown more than a doubling of response rates, driven primarily by cellular and bispecific antibody therapies, while maintaining low treatment-related mortality. These results provide risk-benefit trends in early-phase trials and define contemporary benchmarks for clinicians, investigators and regulators. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Spanjaart AM, Bakker M, de Vries R, et al. Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis. Lancet Haematol. 2026. PMID: 42069410. doi:10.1016/S2352-3026(26)00045-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。